PMA device
ReCor Paradise® Ultrasound Renal Denervation System
Recor Medical, Inc. · Ablation Catheter, Renal Denervation (QYI, Class III) · First FDA decision Feb 5, 2024, newest Feb 5, 2024High blood pressure (hypertension)
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
10
Naming "ReCor Paradise"
MAUDE reports
1
Brand "ReCor Paradise", since 2015
PubMed studies
0
Mentioning "ReCor Paradise"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ReCor Paradise® Ultrasound Renal Denervation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ReCor Paradise® Ultrasound Renal Denervation SystemPMA supplement
P220023-S002 · Decided Feb 5, 2024 · 59 days after receipt · Normal 180 Day Track No User Fee
Device type: Ablation catheter, renal denervation (QYI) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Renal Denervation for Uncontrolled HypertensionNational analysisReview closedCAG-00470NUpdated Sep 22, 2026
- Renal Denervation (RDN) for Uncontrolled HypertensionNational determinationOn the books20.40Updated Mar 24, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "ReCor Paradise", any status and sponsor, newest update first.
ReCor Medical, Inc.Not on our public-company list
NCT06297291 · 1,000 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2028
Device: Paradise Ultrasound Renal Denervation Treatment · For: Hypertension; Cardiovascular Diseases; Vascular Diseases
Sites: Long Beach, California; Los Angeles, California; Sacramento, California · 46 sites in all
- The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II HypertensionPivotal-lookingActive, not recruiting
ReCor Medical, Inc.Not on our public-company list
NCT03614260 · 224 participants · Start Dec 14, 2018 · Primary completion Dec 21, 2022
Device: Paradise Renal Denervation System · For: Hypertension; Vascular Diseases; Cardiovascular Diseases
Sites: Birmingham, Alabama; Los Angeles, California; Bridgeport, Connecticut · 47 sites in all
- The RADIANCE CED StudyRecruiting
ReCor Medical, Inc.Not on our public-company list
NCT07231757 · 1,000 participants (planned) · Start Nov 21, 2025 · Primary completion Dec 31, 2029
Device: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) · For: Hypertension; Cardiovascular Diseases; Vascular Diseases
Sites: Detroit, Michigan · 2 sites in all
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ReCor Paradise", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 0 injury, 0 death
Whole product code QYI
47 reports: 13 malfunction, 33 injury, 0 death
Newest reports for this brand
- RECOR PARADISEOther
MW5158296 · Received Aug 9, 2024
Device type: Ablation Catheter, Renal Denervation (QYI)
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1654-2026 · Started Jan 29, 2026 · Posted by FDA Mar 27, 2026
Reason given: Due to firm distributing a nonconforming product that supposed to be scrapped and not for human use.
Cause as FDA categorized it: Under Investigation by firm · Device type: Ablation Catheter, Renal Denervation (QYI)
Z-1655-2026 · Started Jan 29, 2026 · Posted by FDA Mar 27, 2026
Reason given: Due to firm distributing a nonconforming product that supposed to be scrapped and not for human use.
Cause as FDA categorized it: Under Investigation by firm · Device type: Ablation Catheter, Renal Denervation (QYI)
Published research
The most relevant PubMed records for "ReCor Paradise"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QYI.
- Symplicity Spyral Renal Denervation SystemMedtronic, Inc. · PMA 2026
- Paradise Ultrasound Renal Denervation System (Paradise System)Recor Medical, Inc. · PMA 2026
- Symplicity G3 Renal Denervation RF GeneratorMedtronic, Inc. · PMA 2025
- Symplicity Spyral Multi-Electrode Renal Denervation CatheterMedtronic, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.